Physician profile
Kevin Koehler
NPI 1093034746
$9,627.83
in general payments reported to CMS, 2019-2025
29 companies · $77.99 in 2025
The $77.99 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,579 · 2020: $1,903 · 2021: $5,852 · 2022: $39.87 · 2023: $25.49 · 2024: $150 · 2025: $77.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $175.64 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $5,875.36 | 2019-2021 | |
| Celgene Corporation | $2,137.46 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $231.35 | 2019 | |
| Novartis Pharmaceuticals Corporation | $203.74 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $182.17 | 2019-2021 | |
| Kite Pharma, INC. | $130.99 | 2024 | Yescarta |
| Pfizer INC. | $123.35 | 2019-2020 | |
| Lilly USA, LLC | $109.83 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $92.47 | 2019-2020 | |
| Incyte Corporation | $77.99 | 2025 | |
| Genzyme Corporation | $72.91 | 2019-2022 | |
| Abbvie INC. | $68.56 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $57.67 | 2019 | |
| Emd Serono, INC. | $41.15 | 2019 | |
| Genentech USA, INC. | $27.35 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Heron Therapeutics, INC. | $24.94 | 2019 | |
| Eusa Pharma (US) LLC | $22.95 | 2019 | |
| Tersera Therapeutics LLC | $22.30 | 2019 | |
| Glaxosmithkline, LLC. | $18.71 | 2020 | |
| Janssen Biotech, INC. | $15.61 | 2019 | |
| Puma Biotechnology, INC. | $15.30 | 2019 | |
| Gilead Sciences, INC. | $14.75 | 2019 | |
| Astellas Pharma US INC | $14.21 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.70 | 2019 | |
| Jazz Pharmaceuticals INC. | $11.66 | 2020 | |
| Rigel Pharmaceuticals, INC. | $10.99 | 2020 | |
| Exelixis INC. | $10.85 | 2019 | |
| Veracyte, INC. | $0.51 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Koehler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.